Table 2 Preclinical studies of protein degrader presented at ASH 2023
Compound | Modality | Target | Indication | Reference |
|---|---|---|---|---|
NXD02 | PROTAC | BCL-XL | AML | [5] |
WH25244, PZ18753b | PROTAC | BCL − 2/ BCL-XL | VR CLL | [6] |
DT2216 | PROTAC | BCL-XL | JAK2-mut AML (post-MPN) | [7] |
K-256 | PROTAC | BET | MYC/BCL2-related lymphoma | [8] |
KT-333 | PROTAC | STAT3 | VR AML, VR DLBCL | [9] |
Mezigdomide | molecular glue | Aiolos/Ikaros | MM | [10] |
PinA1 | molecular glue | CK1α | AML | [11] |